Myeloproliferative disorders, now formally called myeloproliferative neoplasms (MPNs), are a group of chronic blood cancers in which the bone marrow overproduces one or more types of blood cells. They arise from a single mutated blood-forming stem cell that gains a growth advantage and gradually crowds out normal blood production. The word “neoplasm” replaced “disorder” in the medical literature because these conditions are clonal, meaning every abnormal cell traces back to one rogue ancestor cell, which places them firmly in the cancer category even though many people live with them for years or decades. Despite that relatively slow pace, MPNs carry real risks of blood clots, bleeding, and transformation into acute leukemia, so understanding them matters well beyond their technical classification.
What Counts as a Myeloproliferative Neoplasm
MPNs are broadly split into two camps based on a single genetic landmark. The first is chronic myeloid leukemia (CML), defined by the Philadelphia chromosome, an abnormal fusion of two chromosomes that creates the BCR-ABL protein with permanently switched-on signaling that drives white blood cell overproduction.1PubMed Central. The Philadelphia chromosome in leukemogenesis The second camp, the Philadelphia-chromosome-negative MPNs, includes three main diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Each overproduces a different cell line. PV makes too many red blood cells, ET makes too many platelets, and PMF progressively scars the bone marrow with fibrous tissue while pushing blood production into the spleen and liver.2Europe PMC / Korean Journal of Hematology. The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteria
There are rarer subtypes too, such as chronic neutrophilic leukemia and chronic eosinophilic leukemia, but PV, ET, PMF, and CML account for the vast majority of cases and are the focus of most research and treatment guidelines.
The Mutations Behind the Overproduction
Almost every MPN can be traced to a specific genetic driver. For CML, it is the BCR-ABL fusion protein, a tyrosine kinase that is stuck in the “on” position, pushing cells to keep dividing and resist normal death signals. BCR-ABL activates several downstream pathways at once, which is why it is such a potent driver of uncontrolled cell growth.3PubMed. BCR-ABL: The molecular mastermind behind chronic myeloid leukemia
For the Philadelphia-negative MPNs, the most common culprit is a mutation in the JAK2 gene called V617F, found in almost all PV patients and roughly half of those with ET or PMF. This mutation produces a version of the JAK2 protein that is always active, constantly telling the cell to grow and survive when it should not be.4Hematology, Transfusion and Cell Therapy. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview Patients who lack a JAK2 mutation often carry a mutation in the CALR gene (calreticulin) or, less commonly, in the MPL gene (the thrombopoietin receptor). CALR mutations were identified in 2013 and were found in about two-thirds of ET patients and nearly nine in ten PMF patients who lacked JAK2 or MPL mutations.5PubMed. Somatic mutations of calreticulin in myeloproliferative neoplasms These three mutations are mutually exclusive in the vast majority of cases, meaning a patient’s disease is typically driven by one of them rather than by a combination.
The specific CALR mutation subtype also shapes the clinical picture. Type 1 CALR mutations, which involve a larger deletion, are more strongly associated with a myelofibrosis-like pattern and a higher risk of fibrotic transformation. Type 2 mutations, a smaller insertion, tend to produce an ET-like course with very high platelet counts but a more indolent trajectory and lower thrombosis risk.6PubMed Central. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms Knowing the mutation subtype helps clinicians predict how a patient’s disease will behave over time.
How a Single Cell Becomes a Disease Over Decades
MPNs do not appear overnight. The initiating mutation occurs in a single hematopoietic stem cell, the type of cell that sits at the top of the blood-production hierarchy and gives rise to all blood cell types. That mutant cell gains a subtle survival or growth edge over its normal neighbors and slowly expands into a clone that eventually dominates blood production.7PubMed Central. Myeloproliferative neoplasm stem cells Lineage-tracing studies have confirmed that this expansion can take decades before the disease becomes clinically apparent.8Haematologica. Evolution of myeloproliferative neoplasms from normal blood stem cells
Researchers reconstructed the evolutionary history of two patients with ET by sequencing their stem cells and using somatic mutations as a molecular clock. In a 34-year-old patient, the disease-initiating JAK2 mutation was estimated to have occurred roughly 25 years before sampling, meaning the mutation likely arose around age nine. In a 63-year-old patient, the mutation dated back about 40 years, placing its origin in early adulthood.9Cell Stem Cell. Clonal Evolution and Fitness in Myeloproliferative Neoplasms These findings underscore that by the time a person receives a diagnosis, the mutant clone has often been expanding quietly for much of their life.
A Closer Look at Each Major Subtype
Polycythemia Vera
PV is defined by excessive red blood cell production, but it can also raise white blood cell and platelet counts. It almost always carries a JAK2 mutation. Beyond the abnormal blood counts, PV brings symptoms like itching (often triggered by warm water), fatigue, an enlarged spleen, and a distinctly increased risk of blood clots. Over time, some patients progress to a fibrotic phase resembling myelofibrosis, and a smaller fraction develop acute myeloid leukemia.10PubMed. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
Essential Thrombocythemia
ET is characterized by persistently elevated platelet counts due to overproduction of megakaryocytes in the bone marrow. Patients are at increased risk of arterial thrombosis (about 11%), venous thrombosis (about 7%), and bleeding complications (about 8%).11JAMA. Essential Thrombocythemia: A Review An interesting paradox is that very high platelet counts, above one million per microliter, can actually promote bleeding rather than clotting. About a quarter of ET patients present with these extreme counts, and the bleeding risk is linked to an acquired form of von Willebrand syndrome where a clotting factor gets consumed by the overabundant platelets.12PubMed Central. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis ET is generally the most indolent of the three Philadelphia-negative MPNs, but it still carries a long-term risk of transforming into myelofibrosis or leukemia.
Primary Myelofibrosis
PMF is the most aggressive of the three. In this disease, the bone marrow gradually fills with scar tissue (fibrosis), squeezing out normal blood-producing cells and forcing the spleen and liver to take over production, which is why massive spleen enlargement is a hallmark. The fibrosis is driven by inflammatory cytokines, including transforming growth factor-beta (TGF-β), and by abnormal signaling from dysfunctional megakaryocytes.13PubMed Central. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies 14PubMed Central. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β Patients with PMF tend to report the worst symptom burden of all MPNs, with fatigue, night sweats, weight loss, and bone pain dominating their experience.
Why Blood Clots Are the Most Feared Complication
Thrombosis is the leading cause of illness and death in MPN patients, and the mechanism is more complex than simply having too many blood cells. In patients carrying the JAK2 V617F mutation, the white blood cells themselves become pro-inflammatory and pro-clotting. Granulocytes and platelets upregulate genes involved in clot formation, express more adhesion molecules on their surfaces, and show increased readiness to form structures called neutrophil extracellular traps that can clog blood vessels. Red blood cells become stickier and more rigid, increasing vascular resistance. Even the blood vessel walls get involved: endothelial cells in JAK2-mutated patients produce more clot-promoting proteins like von Willebrand factor.15PubMed Central. Novel pathophysiological mechanisms of thrombosis in myeloproliferative neoplasms The result is a clotting risk that goes well beyond what the elevated cell counts alone would predict, which is why even patients with near-normal blood counts can develop clots if the underlying clone is active.
Clots in MPNs are not limited to the usual suspects like deep vein thrombosis or pulmonary embolism. They also occur in unusual locations, particularly the hepatic veins (Budd-Chiari syndrome) and the portal and splenic veins. In fact, when a young person presents with a clot in one of these unusual sites, testing for an underlying MPN is standard practice because it is one of the most common causes.
Progression to Acute Leukemia
All MPNs carry a risk of transforming into acute myeloid leukemia (AML), sometimes called “blast phase” or post-MPN AML. This transformation is associated with very poor outcomes and limited response to standard AML treatments.16PubMed Central. Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies PMF carries the highest transformation risk, followed by PV and then ET. The risk increases with disease duration and with accumulation of additional mutations beyond the original driver. Some treatments, particularly older alkylating agents, were also associated with higher leukemia risk, which is one reason those drugs largely fell out of favor.
How MPNs Are Diagnosed
Diagnosing an MPN requires piecing together several types of information: blood counts, a bone marrow biopsy, and genetic testing.17PubMed Central. Quantitative interpretation of bone marrow biopsies in MPN-What’s the point in a molecular age? Many patients are first flagged because of an abnormal blood count on routine testing, often with no symptoms at all. An elevated hemoglobin or hematocrit points toward PV. Persistently high platelets suggest ET. Anemia combined with an enlarged spleen and tear-drop-shaped red blood cells on a blood smear raises suspicion for PMF.
Molecular testing for JAK2, CALR, and MPL mutations has become central to the diagnostic workup. Finding one of these mutations in the right clinical context can confirm the diagnosis, while their absence narrows the differential. A bone marrow biopsy remains important because the pattern of cell overgrowth and the degree of fibrosis help distinguish between subtypes and establish a baseline for monitoring progression. In CML, the diagnosis hinges on detecting the BCR-ABL fusion gene through cytogenetic or molecular testing.
Treatment Approaches Differ by Subtype and Risk
Treatment in MPNs is guided primarily by the patient’s risk of complications, not by a one-size-fits-all protocol. For PV, the cornerstone is phlebotomy (regular blood draws to bring down the hematocrit) combined with low-dose aspirin. Patients at higher risk for clots, generally those over 60 or with a prior clotting event, add cytoreductive therapy, most commonly hydroxyurea, to suppress the overproduction of cells.18Blood. How I treat patients with polycythemia vera Interferon-alpha is an alternative that has gained traction in younger patients because it can reduce the size of the mutant clone over time, something hydroxyurea does not reliably accomplish.
For ET, the same risk stratification applies. Low-risk patients may need only observation and aspirin. High-risk patients, again defined by age over 60 or a history of thrombosis, are treated with hydroxyurea as a first-line cytoreductive agent. Anagrelide and interferon are alternatives when hydroxyurea is not tolerated.19PubMed. Therapeutic options for essential thrombocythemia and polycythemia vera
Myelofibrosis is a different challenge. The JAK inhibitor ruxolitinib, approved in 2011, was the first targeted therapy for this disease. In a landmark trial, about a third of patients on ruxolitinib achieved at least a 35% reduction in spleen volume by 24 weeks, compared with none in the control group receiving best available therapy. The drug also substantially improved symptoms and quality of life.20PubMed. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis However, ruxolitinib does not cure the disease or meaningfully shrink the mutant clone. When the drug is stopped, symptoms and spleen enlargement typically return, sometimes with a rebound flare driven by accumulated JAK2 protein that gets released from inhibition.21PubMed Central. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications This phenomenon has been termed “persistence” rather than resistance, because the drug continues to work while the patient takes it, but the underlying disease process is merely suppressed, not eliminated.
The only genuinely curative treatment for myelofibrosis is an allogeneic stem cell transplant, where the patient’s bone marrow is replaced with a donor’s. For patients who survive the first two years after transplant, long-term outcomes are encouraging, with ten-year overall survival around 74%.22PubMed Central. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis Even patients aged 70 and older have been transplanted successfully, with a three-year survival of 55% in a German registry study.23Transplantation and Cellular Therapy. Allogeneic – Adult Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation But transplant carries substantial risks of its own, including graft-versus-host disease and infection, so it is generally reserved for higher-risk patients or those whose disease is progressing despite other therapies.
The Symptom Burden People Do Not See
Because MPNs are chronic and many patients look outwardly healthy, the day-to-day toll is easy for others to underestimate. A large UK study comparing MPN patients with matched controls found significantly worse scores on 25 of 26 symptoms measured. Fatigue was the most common complaint, reported by over 92% of MPN patients. Women reported a heavier symptom burden than men, and patients with myelofibrosis fared the worst across all measures. Quality of life was substantially lower in MPN patients across the board.24American Journal of Hematology. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls This invisible burden is one reason patient advocacy groups have pushed for more attention to symptom management alongside the traditional focus on preventing clots and controlling blood counts.
How the Bone Marrow Itself Changes
The mutant clone does not just passively overproduce blood cells. It actively reshapes its own environment. Research has shown that MPN cells remodel the bone marrow niche, the specialized microenvironment where stem cells normally reside, into a self-reinforcing “leukemic niche.” Leukemic myeloid cells stimulate the bone marrow’s stromal cells to overproduce structurally altered bone-forming cells, which accumulate as inflammatory, fibrosis-promoting cells. This remodeled niche impairs normal blood production, favors the leukemic stem cells, and contributes to the fibrosis that defines PMF.25Cell Stem Cell. Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche Understanding this feedback loop has opened new therapeutic targets, since disrupting the niche might undermine the clone’s advantage even without killing the mutant cells directly.
Who Gets These Diseases
MPNs are uncommon but not rare. Annual incidence rates in the general population are roughly 0.8 to 1.0 per 100,000 for PV, about 1.0 to 2.0 per 100,000 for ET, and around 0.3 to 0.5 per 100,000 for PMF.26PubMed Central. Aetiology of Myeloproliferative Neoplasms 27PubMed. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map CML has a similar incidence to PV and ET. Older age and male sex are the most established risk factors. The median age at diagnosis is typically in the 60s for PV and PMF and the 50s to 60s for ET, though any age group can be affected.
Children and young adults do develop MPNs, but their disease looks different. Pediatric MPN patients have lower rates of the common driver mutations seen in adults, fewer thrombotic events, and less frequent transformation to myelofibrosis or acute leukemia.28PubMed Central. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults This raises interesting questions about whether pediatric MPNs represent the same diseases with different biology or distinct entities that happen to look similar. Diagnostic criteria and treatment guidelines for younger patients are still evolving, since almost all the existing evidence was generated in older adult populations.29Frontiers in Hematology. Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
MPNs and Pregnancy
Because ET in particular can affect women of childbearing age, pregnancy management is a practical concern. MPNs during pregnancy carry elevated risks of miscarriage, placental complications, and thrombosis for the mother. Treatment options narrow considerably because many standard MPN drugs are not safe during pregnancy. Low-dose aspirin is commonly continued, and interferon-alpha is the preferred cytoreductive agent when needed because it does not cross the placenta in meaningful amounts. JAK inhibitors and hydroxyurea are generally avoided. Management requires close collaboration between hematologists and obstetricians, and expert guidance emphasizes individualized risk assessment and monitoring throughout pregnancy.30PubMed. How I treat myeloproliferative neoplasms in pregnancy
Experimental Therapies on the Horizon
The recognition that current JAK inhibitors suppress symptoms without eliminating the disease has fueled a wave of new drug development. Researchers are exploring agents that target different vulnerabilities of MPN cells, including drugs that trigger cell death pathways, agents that modify gene expression through epigenetic mechanisms, therapies aimed at the abnormal bone marrow microenvironment, and inhibitors of alternative signaling pathways.31PubMed Central. Next Generation Therapeutics for the Treatment of Myelofibrosis Several of these are in advanced clinical trials, and early combination strategies pairing JAK inhibitors with these newer agents are being tested to see whether attacking the disease on multiple fronts can achieve deeper and more durable responses than any single drug alone. The goal that remains elusive for most MPN patients, true disease modification that shrinks or eradicates the mutant clone without a transplant, may eventually become achievable as these approaches mature.